Company Overview
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -51.17% |
| 6 Months: | -1.18% |
| 3 Months: | +13.76% |
| 1 Month: | +28.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.04 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 51.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | APRE Aprea Therapeutics, Inc. PHARMA | 0.84 | -0.89 | $10.58M | 0.00% | -100.49% | -46.15% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | -98.47M | -4.20M | -4.62M | -3.65M | -3.52M | -3.15M | -3.85M | -4.10M | -4.09M | -3.39M | -3.12M | -3.43M |
| Net Income | -3.14M | -3.48M | -5.26M | -6.25M | -9.40M | -16.37M | -12.32M | -9.67M | -10.25M | -9.45M | -7.94M | -98.26M | -4.02M | -4.38M | -3.26M | -3.20M | -2.81M | -3.47M | -3.78M | -3.93M | -3.24M | -2.97M | -3.29M |
| Diluted EPS | - | - | - | - | - | - | -0.58 | -0.46 | -0.48 | -0.45 | -7.25 | -86.72 | -2.32 | -1.34 | -0.87 | -0.86 | -0.67 | -0.58 | -0.64 | -0.66 | -0.53 | -0.47 | -0.22 |
| R&D Expense | 2.31M | 3.68M | 4.32M | 4.91M | 9.10M | 10.69M | 8.76M | 6.76M | 6.65M | 6.02M | 4.09M | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | - | - | -37.45M | -113.39M | -15.47M | -14.32M | -13.23M |
| Net Income | -15.19M | -15.53M | -28.06M | -53.48M | -37.13M | -112.66M | -14.29M | -12.96M | -12.60M |
| Diluted EPS | - | - | -4.67 | -50.61 | -34.88 | -67.99 | -3.95 | -2.35 | -1.93 |
| R&D Expense | 13.39M | 14.19M | 20.95M | 37.88M | 23.90M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 66.02M | 133.61M | 92.81M | 56.82M | 30.16M | 22.65M | 23.98M | 15.93M |
| Total Equity | -21.47M | -35.77M | -51.44M | 124.24M | 77.40M | 49.51M | 25.64M | 16.95M | 19.31M | 12.44M |
| Cash & Equivalents | - | - | 65.68M | 130.09M | 89.02M | 53.08M | 28.79M | 21.61M | 22.85M | 14.60M |
| Total Liabilities | - | - | 4.87M | 9.36M | 15.41M | 7.32M | 3.20M | - | - | - |
| Current Liabilities | - | - | 4.87M | 9.06M | 15.33M | 7.32M | 3.20M | 4.39M | 3.36M | 2.76M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.00M | -15.25M | -26.71M | -41.80M | -37.69M | -25.01M | -12.18M | -13.56M | -12.89M |
| Investing Cash Flow | - | -3.70K | -30.90K | -25.71K | - | - | -93.09K | -15.48K | - |
| Financing Cash Flow | 23.34M | 56.37M | 92.58M | 150.95K | 1.75M | 682.97K | 5.14M | 14.82M | 4.64M |
| Capital Expenditure | - | -3.70K | -30.90K | -25.71K | - | - | -93.09K | -15.48K | - |
| Free Cash Flow | - | -15.25M | -26.74M | -41.83M | - | - | -12.27M | -13.57M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| ROE % | 42.5% | 30.2% | -22.6% | -69.1% | -75.0% | -439.3% | -84.3% | -67.1% | -101.3% |
| ROCE % | - | - | - | - | -75.6% | -420.7% | -84.7% | -69.5% | -100.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 8.07% | 1.02M | $771.71K |
| 2 | Vestal Point Capital, LP | 2.78% | 350.00K | $265.96K |
| 3 | Sphera Funds Management Ltd. | 2.14% | 270.00K | $205.17K |
| 4 | Nantahala Capital Management, LLC | 1.63% | 205.76K | $156.36K |
| 5 | Renaissance Technologies, LLC | 0.84% | 105.80K | $80.40K |
| 6 | Geode Capital Management, LLC | 0.59% | 74.87K | $56.89K |
| 7 | Citadel Advisors Llc | 0.47% | 58.60K | $44.53K |
| 8 | BNP Paribas Financial Markets | 0.36% | 45.21K | $34.35K |
| 9 | Diadema Partners LP | 0.36% | 44.91K | $34.12K |
| 10 | Vanguard Fiduciary Trust Co | 0.31% | 38.46K | $29.23K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for APRE
APRE Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE03OURtalpTZkJnZlI2c0djNlFtR2w1ZXEzdG1VUmFHWTBHX21qWjAyM0d0UEt4SjlRMUxwekpWa1FaN2dLV1BrUUNGUXVIZ0V3YTNHSFR3X19mcVhhTk9MUlhHVU5SNGtDaGJaQ1ZrMWtFQWNyb3k0ZFJR?oc=5" target="_blank">APR…
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxQOWRyOXFBVDdjdUw1aVZSX2VSckJGR1Jac2hiWXVFS2loVk1qUXhuN2ZaQ2ZUYmh1ZVlqTzZ5eGJoRS1jVDF6Z3BHbnotN0otZjhKV05IbFNqMW5VXy1VMjEyQ2tGWUVETlNNbTFQMWZPUV9jRHFBNEIxZTUzalFrS2tCSHVrZmt1bzJ6Q2…
$APRE stock is up 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOeGhqWXZVaE45YVBOcno0NlVnV05UaHB6NXZRWlAzc3kxVEcya19LV05EUUNlVkltYXB2NERVdXpRb2lIclhMMThYWm1keEhJS3ZuWHhKN2FwTVpkNnAxSVVSRG1PUkprWE5ycklVOWxwWnRDSVBBcGxZeGRINC1RS3ZpaEliRU9nRjdTaV…
Aprea Therapeutics records second consecutive surge, jumping another 22% (APRE:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQelB6UnJpQm9fUWU3NzF1bkFJT3N5UUFnTTFzcGZkODJBSEZHUFRBbXZuRTAyR0pLTTB6VWo2WlBCX1ZzcEFfQmY4N2w1X1V2WlB0UGZvSUdEckU0RnNEMEs0NDRyMVZoUmJGWjdPVWZoZmwzVXpIM2FEZkRwRDhCVk5Sek14WHJBRUdwck…
APRE - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1QLWg5S3NxQlhyY1VzUFhqVHp6SllrQTdNT1pka2tNVlhjUmNZS1RGdl9hQkh4Sk1kdHJmclgtQktBOUkzZkE?oc=5" target="_blank">APRE</a> <font color="#6f6f6f">Finviz</font>…
Aprea Therapeutics (NASDAQ: APRE) wins 180-day extension to meet $1 bid - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQZDJHeVRPbzl2eDY0R0xDeFVZR1QxNHdfQ0VTRU9VMlBBLTJrOHJjNEs5VF9LRm9TZHQ5b1UwMmNMX1F5c0lJMXVYYnlwZ05FUXFNTkdBTTU3Y2dsUkxuOHFaQXloZlNxbjIxUFEyVkRpVXNDWVFaSHlUWWRuTmhIb3VtS0JEM3FGbjRwNX…
APRE — Frequently Asked Questions
What is the current share price of Aprea Therapeutics, Inc. (APRE)?
As of 2026-09-19 21:16 PDT, Aprea Therapeutics, Inc. (APRE) trades at $0.84 on NasdaqCM. Its 52-week range is $0.59 to $1.71.
What is the market capitalisation of APRE?
Aprea Therapeutics, Inc. (APRE) has a market capitalisation of $10.58M on NasdaqCM.
What is the P/E ratio of APRE?
APRE trades at a trailing price-to-earnings (P/E) ratio of -0.89. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.25.
What is the return on equity (ROE) of APRE?
APRE has a return on equity (ROE) of -46.15%. Its return on capital employed (ROCE) is -100.49%.
Is APRE a good stock to buy?
This page provides a data-driven analysis of Aprea Therapeutics, Inc. (APRE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.